This company listing is no longer active
MDXH Stock Overview
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
MDxHealth SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.02 |
| 52 Week High | €6.90 |
| 52 Week Low | €1.98 |
| Beta | 0.79 |
| 1 Month Change | 5.19% |
| 3 Month Change | 11.44% |
| 1 Year Change | -52.29% |
| 3 Year Change | -66.07% |
| 5 Year Change | -81.31% |
| Change since IPO | -96.03% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge
Oct 05
MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?
Aug 29MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt
Apr 21Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?
May 05Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money
Nov 08MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?
Mar 23MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years
Jan 29
Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?
Nov 27Shareholder Returns
| MDXH | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | -5.6% | 2.5% | 1.6% |
| 1Y | -52.3% | 16.5% | 3.6% |
Return vs Industry: MDXH underperformed the Belgian Biotechs industry which returned -7.7% over the past year.
Return vs Market: MDXH underperformed the Belgian Market which returned 1.2% over the past year.
Price Volatility
| MDXH volatility | |
|---|---|
| MDXH Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in BE Market | 6.9% |
| 10% least volatile stocks in BE Market | 2.3% |
Stable Share Price: MDXH's share price has been volatile over the past 3 months.
Volatility Over Time: MDXH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 255 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA Fundamentals Summary
| MDXH fundamental statistics | |
|---|---|
| Market cap | €82.41m |
| Earnings (TTM) | -€41.04m |
| Revenue (TTM) | €58.31m |
1.4x
P/S Ratio-2.0x
P/E RatioIs MDXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXH income statement (TTM) | |
|---|---|
| Revenue | US$63.69m |
| Cost of Revenue | US$25.20m |
| Gross Profit | US$38.48m |
| Other Expenses | US$83.30m |
| Earnings | -US$44.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | 60.42% |
| Net Profit Margin | -70.37% |
| Debt/Equity Ratio | 201.8% |
How did MDXH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/18 19:49 |
| End of Day Share Price | 2023/12/18 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MDxHealth SA is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ruzic-Gauthier | Berenberg |
| Mark Massaro | BTIG |
| Roderick Verhelst | Degroof Petercam |